Outpatient Induction of Labour Using Intracervical Foley Catheter (OFC)

January 15, 2025 updated by: Zahar Azuar Zakaria, Hospital Kemaman

Outpatient Cervical Ripening With Foley Catheter for Induction of Labour in Low Risk Women: a Quasi-experimental Study (OFC Study)

Prospective quasi-experimental study between a study population who will receive outpatient induction of labour using intracervical Foley catheter, followed by the inpatient induction using intravaginal prostaglandin and a control group of women with similar characteristics undergoing inpatient labour induction with intravaginal prostaglandin (standard management)

Study Overview

Detailed Description

The study will be conducted among pregnant women in 2 to 5th pregnancy who have no significant risk factors and planned for induction of labour. The eliiable women will be recruited from 4 health clinics within the district (of Kemaman, Malaysia) and located within 20 km from the hospital.

Willing participants will be seen in the hospital at the planned induction date and reassessed. Should they be suitable for induction of labour using Foley catheter on outpatient basis, a 18G Foley catheter will be inserted into the cervical canal and the balloon inflated with sterile water (60 mls). The fetal well being will be assessed and the women allowed to go home with instruction related to the induction and the study.

Those who do not enter the active phase of labour will be admitted to the ward 24 hours later and will undergo inpatient induction of labour using intravaginal prostaglandin (Dinoprostone) according to the local protocol.

These women will be compared with a control group comprising of women with similar characteristics and undergo inpatient induction of labour with intravaginal Dinoprostone.

Study Type

Interventional

Enrollment (Actual)

88

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Terengganu
      • Kampong Kemaman, Terengganu, Malaysia, 24000
        • Hospital Kemaman

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 46 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age > 18 year old
  • Singleton pregnancy
  • Cephalic presentation
  • Multiparous women in their 2nd to 5th pregnancy (Para 1 to 4)
  • Gestational age between 37+0 and 41+0 weeks.
  • No previous uterine surgery (lower segment caesarean section, upper segment caesarean section, myomectomy
  • Resides within 30 minutes drive from Hospital Kemaman
  • Has access to a telephone
  • Has reliable transportation (i.e. able to get to the hospital immediately without the need of ambulance)
  • Acceptance of participation by the signing of a written consent.

Exclusion Criteria:

  • Pregnancy with non-cephalic presentation
  • Prior cesarean delivery
  • Gestational hypertension or preeclampsia on 2 or more medications
  • Diabetes in pregnancy on high dose medication(s); insulin of more than 60 units per day or combination of insulin and oral hypoglycemic agent
  • Low lying placenta or placenta praevia
  • Rupture of amniotic membrane
  • Primiparae and grandmultiparae (para 5 or more)
  • Multiple pregnancy
  • Fetal death
  • Fetal anomalies: defined as the presence of a major fetal anomaly of any organ system
  • Fetal growth restriction: defined as an ultrasound derived estimated fetal weight less than the 10th percentile for gestational age
  • Suspected macrosomia: defined as an ultrasound derived estimated fetal weight of more than 90th centile for gestational age
  • Oligohydramnios: ultrasound measured amniotic fluid index (AFI) less than the 10th percentile for gestational age
  • Polyhydramnios: defined as an AFI of 24 cm or greater or a single deepest vertical pocket of 8 cm or greater
  • Latex allergy
  • Contraindication to induction of labor
  • Evidence of active phase of labor

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intervention
Women who are planned for elective delivery for obstetric indication(s) and undergo outpatient induction of labour using Foley catheter
Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
Other Names:
  • urinary catheter
Insertion of intravaginal Dinoprostone
Other Names:
  • Dinoprostone
Placebo Comparator: Control
Women who are planned for elective delivery for obstetric indication(s) and undergo inpatient induction of labour using intravaginal prostaglandin
Insertion of intravaginal Dinoprostone
Other Names:
  • Dinoprostone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Induction of labour-delivery interval
Time Frame: Induction of labour (intravaginal prostaglandin) to delivery
The mean interval between the start of inpatient cervical ripening and delivery (from the start of cervical ripening with Dinoprostone to the delivery of the baby)
Induction of labour (intravaginal prostaglandin) to delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Success rate of induction of labour within 12 hours
Time Frame: From the start of inpatient cervical ripening and delivery
The percentage of vaginal delivery within 12 hours of inpatient cervical ripening
From the start of inpatient cervical ripening and delivery
Success rate of induction of labour within 24 hours
Time Frame: From the start of inpatient cervical ripening and delivery
The percentage of vaginal delivery within 24 hours of inpatient cervical ripening
From the start of inpatient cervical ripening and delivery
Delivery outcome
Time Frame: Induction to delivery
Percentage of caesarean section and instrumental delivery
Induction to delivery
Adverse event
Time Frame: Induction to delivery
Incidence of uterine tachysystole and hyperstimulation
Induction to delivery
Labour augmentation
Time Frame: Induction to delivery
Duration and maximum oxytocin dose used for labour augmentation
Induction to delivery
Maximum pain recorded
Time Frame: Induction to delivery
Maximum recorded contraction pain during cervical ripening (using Visual Analogue Scale of 10)
Induction to delivery
Incidence of chorioamnionitis
Time Frame: Induction to 24 hours after delivery
maternal temperature is greater than or equal to 39.0°C or when the maternal temperature is 38.0-38.9°C and one additional clinical risk factor is present
Induction to 24 hours after delivery
Analgesia requirement
Time Frame: Induction to delivery
Prevalence of analgesia required during induction of labour
Induction to delivery
Postpartum hemorrhage
Time Frame: Delivery to 24 hours after delivery
Primary postpartum haemorrhage (blood loss of more than 500mls within 24 hours of delivery)
Delivery to 24 hours after delivery
Neonatal Apgar score
Time Frame: Delivery to 10 minutes after birth
Incidence of low Apgar score (less than 7) at 5 minutes after delivery
Delivery to 10 minutes after birth
Neonatal intubation
Time Frame: Delivery to 30 minutes after birth
Incidence of neonates requiring intubation
Delivery to 30 minutes after birth
Neonatal seizure
Time Frame: Delivery to 24 hours after birth
Incidence of neonate with seizure
Delivery to 24 hours after birth
Neonatal complication
Time Frame: Delivery to 24 hours after birth
Admission to the Neonatal Intensive Care Unit
Delivery to 24 hours after birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Zahar Zakaria, MD, Hospital Kemaman

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

September 1, 2024

Study Completion (Actual)

September 1, 2024

Study Registration Dates

First Submitted

November 14, 2022

First Submitted That Met QC Criteria

November 14, 2022

First Posted (Actual)

November 21, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 15, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • NMRR ID-22-00349-EQQ

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share for now

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

Clinical Trials on Foley catheter

Subscribe